Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Clinical comparison of platelet-rich plasma injection and daily celecoxib administration in the treatment of early knee osteoarthritis: A randomized clinical trial

Rubén Reyes-Sosa, Agustin Lugo-Radillo, Lizzet Cruz-Santiago, Celia Rubí García-Cruz, Oliver Mendoza-Cano

. 2020 ; 18 (2-3) : 41-45.

Language English Country Czech Republic

Document type Evaluation Study

Background: Oral and topical nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics and intra-articular corticosteroid injections are the recommended first line of treatment for knee osteoarthritis (OA); however, they have serious side effects. Platelet-rich plasma (PRP) has been posited as an effective and safer alternative treatment for knee OA. Hitherto, there is only one study comparing the effectiveness of PRP against an NSAID. Aim of the study: The aim of this study was to determine the effectiveness of PRP against celecoxib in the treatment of early knee OA. Methods: 60 patients with knee OA grade II and III were randomly alocated in two groups. Group 1 received one injection of autologous PRP in each affected knee, with a reinjection after 15 days; Group 2 received 200 mg of oral celecoxib each 24 h for a year. Visual Analogue Scale (VAS), total Western Ontario and McMaster Universities Arthritis Index (WOMAC) and WOMAC subscales for pain, stiffness and function were measured at baseline and at 1, 3, 6 and 12 months after the start of the treatment. Results: At the end of the study PRP was significantly better than celecoxib (p < 0.05) in improving VAS (40.40%), total WOMAC (58.95%) and WOMAC subscales of pain (50.60%), stiffness (34.13%) and function (51.90%). Significant differences remained after adjusting for age, sex or knee OA grade II or III. Conclusions: Intra-articular PRP is significantly better than celecoxib in improving pain, function and stiffness in early knee OA. This significant difference is independent of age, sex or knee OA grade II or III.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20017238
003      
CZ-PrNML
005      
20210427103634.0
007      
ta
008      
201102s2020 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.32725/jab.2020.012 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Reyes-Sosa, Rubén $u Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Oaxaca, Mexico
245    10
$a Clinical comparison of platelet-rich plasma injection and daily celecoxib administration in the treatment of early knee osteoarthritis: A randomized clinical trial / $c Rubén Reyes-Sosa, Agustin Lugo-Radillo, Lizzet Cruz-Santiago, Celia Rubí García-Cruz, Oliver Mendoza-Cano
504    __
$a Literatura
520    9_
$a Background: Oral and topical nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics and intra-articular corticosteroid injections are the recommended first line of treatment for knee osteoarthritis (OA); however, they have serious side effects. Platelet-rich plasma (PRP) has been posited as an effective and safer alternative treatment for knee OA. Hitherto, there is only one study comparing the effectiveness of PRP against an NSAID. Aim of the study: The aim of this study was to determine the effectiveness of PRP against celecoxib in the treatment of early knee OA. Methods: 60 patients with knee OA grade II and III were randomly alocated in two groups. Group 1 received one injection of autologous PRP in each affected knee, with a reinjection after 15 days; Group 2 received 200 mg of oral celecoxib each 24 h for a year. Visual Analogue Scale (VAS), total Western Ontario and McMaster Universities Arthritis Index (WOMAC) and WOMAC subscales for pain, stiffness and function were measured at baseline and at 1, 3, 6 and 12 months after the start of the treatment. Results: At the end of the study PRP was significantly better than celecoxib (p < 0.05) in improving VAS (40.40%), total WOMAC (58.95%) and WOMAC subscales of pain (50.60%), stiffness (34.13%) and function (51.90%). Significant differences remained after adjusting for age, sex or knee OA grade II or III. Conclusions: Intra-articular PRP is significantly better than celecoxib in improving pain, function and stiffness in early knee OA. This significant difference is independent of age, sex or knee OA grade II or III.
650    _2
$a lidé $7 D006801
650    _2
$a výsledek terapie $7 D016896
650    _2
$a osteoartróza $x farmakoterapie $x terapie $7 D010003
650    _2
$a trombocyty $7 D001792
650    _2
$a plazma bohatá na destičky $7 D053657
650    _2
$a injekce intraartikulární $7 D007270
650    _2
$a antiflogistika nesteroidní $7 D000894
650    _2
$a revmatické nemoci $7 D012216
655    _2
$a hodnotící studie $7 D023362
700    1_
$a Lugo-Radillo, Agustin $u CONACYT - Universidad Autónoma Benito Juárez de Oaxaca, Faculty of Medicine and Surgery, Oaxaca, Mexico
700    1_
$a Ruiz-Olivera, Maria del Rocio $u Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Oaxaca, Mexico
700    1_
$a Cruz-Santiago, Lizzet $u Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Oaxaca, Mexico
700    1_
$a García-Cruz, Celia Rubí $u Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Oaxaca, Mexico
700    1_
$a Mendoza-Cano, Oliver $u Universidad de Colima, Faculty of Civil Engineering, Colima, Mexico
773    0_
$t Journal of applied biomedicine $x 1214-021X $g Roč. 18, č. 2-3 (2020), s. 41-45 $w MED00012667
856    41
$u https://jab.zsf.jcu.cz/pdfs/jab/2020/02/02.pdf $y plný text volně přístupný
910    __
$a ABA008 $b B 2301 $c 1249 $y p $z 0
990    __
$a 20201102142735 $b ABA008
991    __
$a 20210415103624 $b ABA008
999    __
$a ok $b bmc $g 1578635 $s 1107424
BAS    __
$a 3
BMC    __
$a 2020 $b 18 $c 2-3 $d 41-45 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
LZP    __
$c NLK197 $d 20210415 $a NLK 2020-40/dk

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...